TY - JOUR
T1 - Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection
AU - Iranmanesh, Ali
AU - Gullapalli, Dakshinamurty
AU - Singh, Ravinder
AU - Veldhuis, Johannes D.
N1 - Funding Information:
This study was funded in part by the National Institutes of Health in Bethesda, MD [R01 DK073148 (JDV)], and the Salem Research Institute of the Salem VA Medical Center (AI). The Mayo Immunochemical Laboratory provided assistance with mass spectrometry (RJS). Supported in part via R01 DK073148 (JDV) from the National Institutes of Health (Bethesda, MD), and the Salem Research Institute of the Salem VA Medical Center (AI). Contents are solely the responsibility of the authors and do not necessarily represent the official views of any federal institution.
Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Purpose: To quantify adrenocorticotropin and cortisol secretion after epidural glucocorticoid injection. Methods: Eight men (ages 25–63 year) were studied at baseline, 1, 4, and 12 weeks after triamcinolone (80 mg) injection epidurally. Adrenocorticotropin (pg/mL) and cortisol (µg/dL) were measured every 10 min for 4 h, and after Corticotropin-releasing hormone (CRH) (1 µg/kg) injection. Results: Epidural triamcinolone markedly suppressed: (1) pre-CRH injection ACTH (from 18 ± 3.1 to 4.8 ± 0.4: P < 0.01) and cortisol (from 12.2 ± 1.6 to 1.6 ± 0.3: P < 0.0001) at week 1, with recovery at 4 weeks, and (2) CRH-stimulated 3-h summed ACTH (from 633 ± 116 to 129 ± 10 pg/mL, P < 0.0001), and 3-h summed cortisol at week 1 (from 385 ± 29 to 56 ± 22 µg/dL, P < 0.0001) and 4 weeks (284 ± 53; P < 0.01). Serum cortisol was <18 µg/dL in eight of eight men at 4 weeks, and six of eight men at week 12. Urinary-free cortisol (µg/24 h) remained low at week 12: baseline (60 ± 6.5); week 1 (9.0 ± 1.3, P < 0.01); week 4 (36 ± 8.6) and week 12 (38 ± 4.1). Urinary cortisol/cortisone ratios rose at week 4 only. Serum triamcinolone peaked at week 1 (16/16 samples), declining at week 4 (13/16 samples) and week 12 (6/16 samples). Limitations: Relatively small group. Conclusion: Epidural triamcinolone suppresses unstimulated and CRH-stimulated ACTH and cortisol secretion for 1–4 weeks but urinary free cortisol ≥12 weeks. Suppression of ACTH and cortisol after glucocorticoid treatment is thus complex.
AB - Purpose: To quantify adrenocorticotropin and cortisol secretion after epidural glucocorticoid injection. Methods: Eight men (ages 25–63 year) were studied at baseline, 1, 4, and 12 weeks after triamcinolone (80 mg) injection epidurally. Adrenocorticotropin (pg/mL) and cortisol (µg/dL) were measured every 10 min for 4 h, and after Corticotropin-releasing hormone (CRH) (1 µg/kg) injection. Results: Epidural triamcinolone markedly suppressed: (1) pre-CRH injection ACTH (from 18 ± 3.1 to 4.8 ± 0.4: P < 0.01) and cortisol (from 12.2 ± 1.6 to 1.6 ± 0.3: P < 0.0001) at week 1, with recovery at 4 weeks, and (2) CRH-stimulated 3-h summed ACTH (from 633 ± 116 to 129 ± 10 pg/mL, P < 0.0001), and 3-h summed cortisol at week 1 (from 385 ± 29 to 56 ± 22 µg/dL, P < 0.0001) and 4 weeks (284 ± 53; P < 0.01). Serum cortisol was <18 µg/dL in eight of eight men at 4 weeks, and six of eight men at week 12. Urinary-free cortisol (µg/24 h) remained low at week 12: baseline (60 ± 6.5); week 1 (9.0 ± 1.3, P < 0.01); week 4 (36 ± 8.6) and week 12 (38 ± 4.1). Urinary cortisol/cortisone ratios rose at week 4 only. Serum triamcinolone peaked at week 1 (16/16 samples), declining at week 4 (13/16 samples) and week 12 (6/16 samples). Limitations: Relatively small group. Conclusion: Epidural triamcinolone suppresses unstimulated and CRH-stimulated ACTH and cortisol secretion for 1–4 weeks but urinary free cortisol ≥12 weeks. Suppression of ACTH and cortisol after glucocorticoid treatment is thus complex.
KW - ACTH
KW - Cortisol
KW - Glucocorticoid
KW - Human
KW - Inhibition
UR - http://www.scopus.com/inward/record.url?scp=85021833350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021833350&partnerID=8YFLogxK
U2 - 10.1007/s12020-017-1357-7
DO - 10.1007/s12020-017-1357-7
M3 - Article
C2 - 28674775
AN - SCOPUS:85021833350
SN - 1355-008X
VL - 57
SP - 308
EP - 313
JO - Endocrine
JF - Endocrine
IS - 2
ER -